Lupin and Galenicum Sign License and Supply Agreement for Semaglutide in 23 Countries

Lupin Limited, a global pharmaceutical leader based in Mumbai, has entered into a strategic licensing and supply agreement with Galenicum Health for finished formulations of injectable Semaglutide. This partnership, facilitated through Lupin’s subsidiary Lupin Atlantis Holdings SA (LAHSA), targets 23 countries across major markets, including Canada, Europe, Latin America, and Southeast Asia. Under the terms of the deal, Galenicum will be responsible for the development and manufacturing of the product, while Lupin will leverage its global infrastructure to manage regulatory submissions, approvals, and commercialisation.

Semaglutide is a highly sought-after GLP-1 receptor agonist that plays a critical role in regulating blood sugar levels and appetite. Primarily prescribed for adults with Type 2 Diabetes as an adjunct to diet and exercise, it has also gained significant prominence for long-term weight management in individuals dealing with obesity or overweight conditions. This agreement allows Lupin to broaden its specialised portfolio in metabolic health, providing a generic version of a drug that has become a cornerstone of modern diabetes and obesity care.

This collaboration marks a significant expansion of Lupin’s leadership in the diabetes and obesity segments beyond its stronghold in India and the United States. By securing distribution rights in over 20 international territories, the company is positioning itself to capture a substantial share of the growing global demand for complex generic injectables. The move aligns with Lupin's broader strategy to diversify its offerings and improve patient outcomes in high-impact therapy areas where cost-effective generic alternatives are in high demand.

Lupin’s robust operational framework, which includes 15 manufacturing sites and 7 research centres worldwide, provides the necessary scale to support such extensive international rollouts. With a workforce of over 24,000 professionals and a distribution network spanning 100 markets, the company is well-equipped to navigate the complex regulatory landscapes of the 23 countries involved. This partnership reinforces Lupin's commitment to delivering high-quality, complex generic formulations and strengthens its presence in the competitive global biopharmaceutical landscape.

Disclaimer: The article is for informational purposes only and not investment advice.